Fankai Meng
Overview
Explore the profile of Fankai Meng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
836
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhao Y, Luo Y, Shi J, Wang S, Wang C, Jiang E, et al.
Blood
. 2025 Feb;
PMID: 40009501
Rovadicitinib (TQ05105) is a novel, oral dual JAK1/2 and ROCK1/2 inhibitor targeting inflammatory and fibrotic components of chronic graft-versus-host disease (cGVHD). We aimed to evaluate the safety and efficacy of...
2.
Wu J, Liu W, Cao Y, Yang Y, Shang Z, Zhou M, et al.
Cancer Immunol Immunother
. 2024 Nov;
74(1):17.
PMID: 39527142
Background: Several reports have indicated that chimeric antigen receptor (CAR) T-cell therapy following autologous hematopoietic stem cell transplantation (ASCT) is a promising strategy for refractory/relapsed (r/r) central nervous system lymphoma...
3.
Lin H, Deng T, Jiang L, Meng F, Cao Y, Zhang Y, et al.
Cancers (Basel)
. 2024 May;
16(9).
PMID: 38730674
(1) Background: The combination of CAR-T with ASCT has been observed to enhance the efficacy of CAR-T cell therapy. However, the impact of this combination on adverse reactions is still...
4.
Peng Y, Huang J, Yin J, Meng F, Cao Y, Huang L, et al.
Expert Rev Hematol
. 2024 Apr;
17(4-5):173-180.
PMID: 38616308
Background: Studies on dasatinib-based low-intensity induction regimens and post-remission strategies are limited in China. Therefore, we conducted a single-center phase 2 trial in newly diagnosed adult patients with Philadelphia chromosome-positive...
5.
Xin X, Zhu X, Yang Y, Wang N, Wang J, Xu J, et al.
Cell Oncol (Dordr)
. 2024 Apr;
47(4):1425-1440.
PMID: 38564164
Introduction: Chimeric antigen receptor (CAR)-T cells obtained long-term durability in about 30% to 40% of relapsed/refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL). Maintenance therapy after CAR-T is necessary, and PD1 inhibitor...
6.
Li N, Zhang R, Wang J, Zhu X, Meng F, Cao Y, et al.
Front Neurol
. 2024 Mar;
15:1334000.
PMID: 38487325
Background: The development of chimeric antigen receptor (CAR)-T cell therapy has revolutionized treatment outcomes in patients with lymphoid malignancies. However, several studies have reported a relatively high rate of infection...
7.
Fu A, Peng Y, Cheng P, Wu J, Zhu X, Yang Y, et al.
Transplant Cell Ther
. 2024 Mar;
30(5):500-509.
PMID: 38447750
Background: Recombinant human TPO (rhTPO) promotes platelet engraftment in patients after allogeneic HSCT (allo-HSCT). However, the effects of rhTPO on platelet recovery after Haplo-HSCT in patients with severe aplastic anemia...
8.
Wu L, Liu L, Zhao X, Zhou M, Fu A, Zhang Y, et al.
Blood Cancer J
. 2024 Mar;
14(1):37.
PMID: 38443356
No abstract available.
9.
Xin X, Lin L, Yang Y, Wang N, Wang J, Xu J, et al.
Cytotherapy
. 2024 Feb;
26(5):456-465.
PMID: 38385909
Background Aims: The combination therapy of autologous hematopoietic stem cell transplantation (ASCT) and chimeric antigen receptor T-cell (CART) therapy has been employed to improve outcomes for relapsed or refractory (R/R)...
10.
He S, Peng J, Yang X, Meng F, Huang L, Huang L, et al.
Front Biosci (Landmark Ed)
. 2023 Dec;
28(11):299.
PMID: 38062808
Background: Chimeric antigen receptor (CAR) T-cell therapy carries the risk of inducing severe and life-threatening toxicities such as cytokine release syndrome (CRS), neurotoxicity, and infection. Although CRS and infections have...